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Introduction 
The aim  of the  present Communication  is  to  lay  down  the  outlines  of an 
industrial policy for the pharmaceutical sector. This industl)' is a substantial 
asset for growth and employment  in  the  European  Union.  However,  in  the 
context of stiffening world-wide competition and of continuous  incr~es in 
the cost of research and  development  in  this sector, there are signs that the 
competitiveness of the Community industl)' is yielding in comparison with its 
main competitors. Its ability to finance the research and development of new 
therapeutically  innovative medicines,  which  is  a  condition  for  its  long  term 
competitiveness, in particular seems to be relatively weak. 
Although  it  is  essential to ensure that the  European pharmaceutical industry 
retains  its  competitiveness, the  ways and means of this action  must however 
be considered by taking into account the specificity of  this industry. Medicinal 
products  play  an  essential  role  in  the  field  of public  health.  Moreover, 
pharmaceutical  spending  represents  an  important  share  of social  security 
budgets, whose financing is a subject of  concern in most Member States at the 
very  moment  that these  are  required  to  contain  public  deficits  in  order  to 
prepare for  economic and monetary union.  The Community policy in  favour 
of the  pharmaceutical  industl)'  must take  notice of this  twofold  context of 
public health and social security, which - in  conformity with the principle of 
subsidiarity - is ascribable to Member States in the first place. 
By  the  year  2000,  restructuring  and  amalgamation  will  have  radically 
changed  the  face  of the  European  pharmaceutical  industl)'.  The  industrial 
policy for this sector should strive to accompany these changes,  in  order to 
foster  the  emergence  of firms  able  to  stay  in  the  vanguard  of tomorrow's 
global industl)'. Following the way paved by the Commission  White  Paper: 
Growth,  Competitiveness,  Employment, the  Community and  Member States 
must together ensure that the conditions necessary for the competitiveness of 
the EC pharmaceutical industry are in place. 4 
Chapter 1 
Growth, competitiveness, employment in the pharmaceutical sector 
The  European  pharmaceutical  industry  is  a  substantial  asset  for  the  European  economy. 
However,  it would seem  that  it  is  not  well  enough  prepared  to  brace  itself against stiffening 
international competition ~d  with the relentless rise of the cost of  pharmaceutical research, arid 
that its competitiveness could prove insufficient in regard to its majn competitors. The first signs 
of  structural difficulties in this industry have indeed appeared r~ntly 
A) The pharmaceutical industry: an important asset for the European economy 
The pharmaceutical  industry is among Europe's  best-performing high-technology sectors.  It 
generates over I% of EC gross national domestic product and has grown at an annual rate in 
excess of6% between 1982 and 1992. Its production was worth ECU 68 billion in  1992, with 
an average value added of  40%, and it has a very high labour productivity rate. 
As a result of  significant R&D efforts in the past, the EC pharmaceutical trade surplus (nearly 
ECU 4.9 billion in  1992, and growing steadily) has  for many years helped to improve the 
Community trade balance. The position is slightly less favourable for active substances, which 
generate more added value, than for finished or semi-finished products. The site of research 
and production of active substances are often linked.  Overall, however,  EC pharmaceutical 
trade is in surplus with all third countries except EFT  A countries, and to a lesser extent, with 
the United States. 
The pharmaceutical  industry  generates  many jobs upstream,  such  as  basic  and  speciality 
chemicals,  starch  and  sugar  production,  medicinal  plants,  packaging,  special  glass 
manufacturing and computer technology. 
B) Growing research and development costs 
Pharmaceutical  research  is  long  and  costly.  It  takes  10  to  12  years  to  develop  a. newly-
synthesised active substance into a marketable medicine which can be used in current medical 
practice. The average cost of researching and developing an entirely new medicinal product, 
several dozen of which are launched each year on the world market, is estimated at ECU 200 
million. 
Because  such  an  investment  can  be  financed  only  if the  company  is  able  to  generate  the 
necessary  cash  flow  during  the  period  of patent  protection,  it  is  essential  to  launch  the 
medicinal product on the markets of large industrialised countries as quickly as possible. The 
survival of large pharmaceutical companies depends on the profitability of  a small number of 
products (sometimes on that of  just one successful product), and also on the regular renewal 
of  portfolios of  patents on new medicinal products. 5 
Yet total  investment  in  research  and  development  has  quintupled  in  the  past fifteen  years. 
Development costs in particular h~ve soared. This rapid growth in costs is generally attributed 
to progress in molecular biology and especially in knowledge of the pathogenesis of  diseases, 
to technical  improvements  in  tools  for  therapy or prevention,  and to increasingly  stringent 
technical  requirements  designed  to  ensure  the  quality,  safety  and  efficacy  of medicinal 
products.  On  average,  out of every  10,000  substances  synthesised  by  the  pharmaceutical 
industry, only one or two will become marketable medicines. 
C) Stiffening world-wide competition 
The  industry's  globalization  demands  that  companies  expand  their  acttvtttes,  first  within 
Europe, by consolidating their positions, then  world-wide.  Community firms  account for 2/3 
of the market in the EC,  1/3  in  the USA and  I 0% in  Japan. The US  pharmaceutical industry 
has  similar market shares  in  the  EC  and  Japan. The Japanese pharmaceutical  industry has 
80% of its own market, and although it has so far won only  I% of the market in  the US and 
Europe,  is  likely  to  increase  its  penetration  with  new  medicinal  products  researched  and 
developed in Japan and purchased under licence by American and European companies. 
For innovative firms it is  important to  benefit from a substantial home market to generate the 
cash  flow  needed  to  finance  their  research  and  development  costs.  Overall,  the  EC 
pharmaceutical market is  the world's largest:  it accounts for about ECU 63.5 billion in  1992, 
i.e.  about a  third of the total.  But until  all  the measures  adopted  recently  by  the European 
Community are translated into  reality,  this  market will  remain  relatively fragmented  by  its 
many national partitions. The financial resources required to pursue research and development 
efforts will only be available for European pharmaceutical companies if these are allowed an 
effective access to third countries' markets. 
D) The vulnerability of the European pharmaceutical industry 
European pharmaceutical companies  are still  relatively well-placed  in  the  world  ranking:  in 
1992, 8 EC firms appear among the 20 leading pharmaceutical groups. 
The huge risks involved make individual companies very vulnerable, not least because 90% of 
R&D  spending  is  financed  by  the  industry  itself.  It  is  therefore  the  long-term  capacity  to 
generate the resources needed to bring new products to the market - a capacity which depends 
on the success of those already on the market - that determines the ability to compete of the 
principal  multinational  companies.  This  capacity  can  be  measured  by  the  return  on 
investment, which includes net profit and cash flow, as calculated in  world-wide consolidated 
accounts.  Indeed  pharmaceutical  companies  resort only  occasionally to  borrowing to  cover 
R&D costs; in  most cases R&D is  financed  through the allocation of a  share of profits to 
investments required for research programmes. 
On average, European companies generally obtain results vastly inferior to those of American 
companies: for many years,  budgets allocated to R&D investments  by  EC companies  have 
accounted for only half of  the budgets available to American companies. Thus, the operational 
profit of  the 8 top Community pharmaceutical groups, British groups not included, is around 
13%. Only 2 British companies have come close to the ratios achieved by American and Swiss 
companies (around 28%), which  explains the rise of some of the former  in  world  rankings. 6 
Additionally, European companies are, in general, of  a smaller size than US companies, which 
therefore have from the very start greater resources for their R&D spending. 
The concept of  major global drugs encompasses medicinal products which are present on 6 of 
the 7 biggest markets in the world, and is therefore a good indicator of innovation. Today the 
United  States  hold  43%  of these  major  global  drugs,  Europe  31%  and  Japan  II%. 
Furthermore, the capacity of  EC firms to innovate appears to be declining, and they are under-
represented in some new fields. 
Twenty years ago, half of all  new medicines were developed in  the Community. Today, this 
share has fallen to about one-third. Over the same period, the USA has continued to discover 
about a quarter of  all new active substances, whilst Japan has increased its share from 10% to 
22%.  Among  the  medicinal  products  launched  in  Europe  since  1987,  37 originated  in  the 
United States, 28  in  Europe. It is hard to escape the conclusion that the United States, rather 
than Europe,  is  now  the  main  base for  pharmaceutical  research  and development  and  for 
therapeutic innovation. 
The picture is  most worrying in respect of biotechnology: 65% of patents are American, 15% 
European  and  13%  Japanese.  Where  in  the  USA  around  1000  small  and  medium  size 
enterprises arc active in the pharmaceutical field,  there are only 30 such companies in Europe, 
and  they  only  started  to  emerge  in  recent  years.  Among  the  50  new medicinal  products 
appearing each year on the world market, 1  0 to  15  are derived from biotechnological methods. 
This  proportion will  gradually  increase  over  the  next years.  Rapid  technological  progress, 
especially  in  genetics  and  molecular  biology,  have  opened  up  new  areas  of still  untreated 
illness  to  m~ical intervention,  thanks  notably  to  genetic  therapy.  World  pharmaceutical 
consumption is predicted to rise on present trends by 36% or more by the year 2000. Most of 
this growth will be fuelled by the uptake of new products derived from biotechnology. 
E) Employment in the pharmaceutical sector 
The pharmaceutical industry employs almost half a million people directly within the EC.  It 
needs many highly skilled staff, and employs 62,000 people in research. Despite the recession, 
the pharmaceutical industry has been expanding its workforce between  1981  and 1992, by an 
average of 2.4% per year.  Since  the  beginning  of 1993,  however,  this  trend  has  gone  into 
reverse. For the first time in 20 years the total employment in  the pharmaceutical industry did 
not  increase  in  1993,  but  rather  decreased  by  1.4%.  Furthermore  even  more  important 
reductions  of the  workforce  have  already  been  announced  and  will  take place through  the 
coming years. Thus, within three years ( 1993-1995), nearly 27,000 jobs could be  lost in  the 
European pharmaceutical industry.  A substantial part of the lay-off stems from the closing of 
research or manufacturing sites, or delocalizations. 
(  I 
Equally  worrying  is  the  importance  of disinvestment.  Several  companies  have  definitely 
abandoned plans to develop  or to  establish  new  research or manufacturing units.  One  must 
therefore take  into account  th~ fact that,  over  the  next years,  the  European pharmaceutical 
industry will  not be able to  create 5,000 to  10,000 new jobs a year,  as  in  each  of the  last 
years. 7 
F) New approaches and the restructuring of the pharmaceutical industry 
Besides  the  dominant  multinational  firms,  there  are  many  medium-sized  companies  whose 
activities are not world-wide but are nonetheless international. They exploit both the products 
of their own research and other companies' products under licence.  A large number of small 
local  companies,  some working  in  promising  specialised  fields,  complete  the  fabric  of the 
pharmaceutical industry. 
In  Japan, and even more so in  the USA,  much  innovation,  particularly in  the  biotechnology 
and  genetic  engineering  fields,  stems  from  the  dynamism  of  small  and  medium-sized 
enterprises which are more or less independent of large pharmaceutical groups. In Europe, by 
contrast,  SMEs  generally  concentrate  on  traditional  production,  contrary  to  the  situation 
observed in  Japan and especially  in  the  US.  This ultimately exposes the vulnerability of the 
fabric of European industry since the totality of innovative potential is  not fully exploited. Yet 
these companies have a human resource and experience which they should be able to exploit 
more satisfactorily. Given a better access to research at both national and European level, the 
flexibility of  these SMEs could be an important advantage in niche innovation. 
It is also important to take into account some new trends and particularly the development of 
products for self-medication. The turnover for self-medication varies greatly from one country 
to  another  (representing  between  8%  and  17%  of  the  market  in  1992  according  to 
AESGP/IMS). This segment of the market has  experienced an average growth rate of 9.9% 
since 1987, and the demand for these products is  likely to  increase in  future years. This has 
been confirmed  by  the fact  that  many  large  pharmaceutical  companies  are now developing 
their products for  this  segment of the  market,  in  order to  respond  in  certain  cases,  to  the 
change  in  behaviour of patients.  The  Community  has  recently  adopted  directives  on  the 
rational use of medicinal  products which  supply a common  regulatory framework  for these 
medicines  which  arc advertised to the public  in  accordance  with  the conditions  set out in 
Community legislation (directive 92/28/EEC). 
In  some  countries,  collaboration  between  firms,  e.g.  through  co-marketing  ventures  and 
investment by  major multinationals  in  local  research and development and/or manufacturing 
units,  has  helped  to  hatch  a  local  research  industry  later  able  to  position  itself on  world 
markets.  Technical  collaboration  between  world  class  research  companies  and  local 
undertakings closer to the culture of  their markets often results in  marketing agreements, or in 
more elaborate joint venture research programmes, which provide development opportunities 
in a growth industry from which these countries would be excluded without the contribution of 
know-how essential to a successful start-up. 
The European pharmaceutical industry's structure was not, of  course, radically changed by the 
advent of the single market in  1993.  Indeed, several measures which were adopted in  view of 
the completion of the internal market still have to come into effect in  this sector. Nonetheless, 
significant changes could occur by the year 2000, and it is  up  to  industrialists to prepare for 
them.  Community initiatives will facilitate the restructuring and rationalisations which should 
allow the EC pharmaceutical industry to become more competitive. 
Firstly, and independently of any  specific  initiative by  the  Community, the structure within 
which  pharmaceutical  companies  arc  used  to  working  has  been  profoundly  shaken  by  the 
soaring cost of pharmaceutical research and development, the emergence of new technologies 8 
such as biotechnology, the international  ~rend towards greater concentration of capital and the 
means of  production. 
The fragmentation of national  markets had  led to a  dispersion of production sites, and is  a 
considerable source of  waste. Some European companies have yet to take full account in their · 
bus  mess strategies of  the potential· offered by the Community's new regulatory framework 
Although  a  great  number  of enterprises  are  active  in  the  pharmaceutical. industry,  large 
multinational  firms  are each  pre-eminent  in  one  or  more  of the  many  market  segments 
constituted by diverse therapeutic indications. Consequently, the trend for large companies to 
link  up  or merge  is  likely  to  gather  pace  and  to  sweep  up  European  firms  ever  more 
frequently.  · 9 
Chapter 2 
The context : public health and social security 
Thus,  the  Community  has  to  maintain  and  to  reinforce  the  competitiveness  of the  European 
pharmaceutical industry. However Community initiatives in  this field  must take into account the 
specificity of this industry - on the one hand because pharmaceutical products play a key role in 
the context of public health; -on the other hand because the manner in  which the consumption of 
these  products  is  financed  has  a  direct  impact on  the  social  security  budgets  of the  Member 
States. The Community pharmaceutical  policy must be  inserted in  this  twofold  context:  public 
health and social security, although there could be no question of  challenging the Members States' 
competence in this field. 
A) Medicinal products and public health policy 
In  the  field  of public  health,  Article  129  of the  Maastricht  Treaty  provides  that  "the 
Community  shall  contribute  towards  ensuring  a  high  level  of human  health  protection  by 
encouraging co-operation between  the  Member States and,  if necessary,  lending  support to 
their action"- This implies that the Community should improve the collection and exchange of 
data  in  the  field  of public  health,  strengthen  networks  and joint  projects  and  promote  the 
exchange of experience and expertise. The Commission has identified already certain priority 
fields which will be the subject of  pluriannual Community action programmes. 
As proposed by the Commission in its Communication of 24 November 1993 (COM(93)559), 
the Community strategy in the field of public health will aim essentially at fostering the ability 
of each European citizen to protect and to promote its own health by supplying him with the 
necessary information in this respect. This strategy requires the development of new forms of 
preventive medicine as well as other fom1s of prevention linked with hygiene and life-styles. It 
also implies a strengthening of the pharmaceutical industry's ability to supply therapeutic and 
diagnostic means at the best cost. Only if it is effective and competitive will  the EC industry 
be able to significantly contribute to  the struggle against the many diseases not yet mastered 
by  medical  progress, be  it diseases  which are very common  in  developed countries or in  the 
third world, or indeed so-called rare diseases. 
Progress in  medicine and therapeutics has helped greatly to  reduce mortality, prolong life and 
eliminate major diseases. The most spectacular successes have  been  the prevention of many 
scourges (including  childhood  diseases),  through  vaccination  (rabies,  typhoid,  tuberculosis, 
diphtheria, tetanus, whooping cough, poliomyelitis and cholera) and anti-infectious treatments, 
such as antibiotics.  Moreover, new and important progress has been made in  the treatment of 
cardio-vascular diseases and cancer. 
Still, there are many diseases which cannot yet be treated satisfactorily. We have only partial 
answers to some, and new ones appear, or arc identified,  as knowledge  progresses. We still 
lack effective treatments and cures  in  the  important field  of chronic  degenerative diseases, 
which impose the heaviest burden on  public health spending. Wide fields of investigation are 
still opening up  to  researchers  in  the fields  of immunobiology, tropical diseases, AIDS and 10 
gene therapy. These fields are particularly exposed and vulnerable, because success, or even a 
return on investment, is rarely assured. 
A  whole  series  of diseases  (about 5,000  have  been  identified)  are described  as  "orphan", 
because they are too rare, or because developing a treatment for them would be too costly for 
a  private  company  to  venture  investing  the  time · and  money  needed  to  research,  fulfil 
marketing authorisation requirements for, and produce such a treatment. Whilst state support 
may be  obtained fairly  easily for  research  in  fields  which  the general  public  recognises  as 
important, e.g. cancer and AIDS, cystic fibrosis and multiple sclerosis, this is not the case for 
·most other such diseases. 
B) Social security and pharmaceutical spending 
In a difficult economic context and in the transition phase towards Economic and Monetary 
Union, keeping health care cost under control is of increasing concern for all Member States. 
A reduction in the. share of  health care spending which is collectively financed (between 70% 
and 90% according to the Member States) could result in important inequalities based on 
revenue in terms of  access to health care and medical care, in a context where European 
citizens remain, as regards the financial risk involved with disease, deeply attached to the 
principle of  solidarity, which is at the very heart of  their social system. 
The overall  increase  in  health  spending  is  attributable  partly to  impressive  scientific  and 
technical progress particularly in the pharmaceutical field but also to population ageing and to 
the extension of  social security cover. OECD figures show that Europe spent ECU 330 billion 
on public health in  1990.  The enormous health care expectations of European citizens (and 
hence their pharmaceutical consumption) stem from their deep-rooted belief in social solidarity 
and hope for continuous improvements in the quality of life. 
The share of pharmaceutical expenditure in  total social security spending ranges from  nearly 
l 0% to more than 20% in  the Member States (in  1990, according to OECD). As  a share of 
health insurance spending,  it  averages only about  16%, and this share is  in  relative decline, 
compared with rising expenditure on hospital care. 
The  medicinal  product  is  still  the  therapeutic  tool  of choice  which  in  some  circumstances 
achieves a  better cost/bcndit ratio than other treatments.  lt can allow savings to be  made in 
other  health  sectors,  and  helps  to  improve  mcdica(care.  Although  in  most  industrialised 
countries  pharmaceutical  consumption  accounts  for  about  1%  of gross  domestic  product, 
consumption volumes and medicinal  product prices still differ widely from  one EC Member 
State  to  the  next  Differences  in  prescribing  practices  and  pharmaceutical  consumption 
patterns do not always correlate well with the levels of  health protection achieved 
In  most Member States, the entire  population  benefits  from  a  publicly financed  health  care 
cover, as far as  pharmaceuticals arc concerned.  This  is  also reflected  in  the reimbursement 
rate which, in the Community, exceeds half  even two thirds, of  expenses on pharmaceuticals . 
.  , 
The part of  pharmaceutical spending which is not covered by social protection systems is born 
either by private insurance, or by  patients themselves. The cover ratio is generally higher for 
products  which  arc  only  available  on  medical  prescription  and  therefore  for  innovative 
products. 11 
The Community has undertaken to promote a high  level  of social protection and to ensure a 
high  level  of health  protection.  In  its  Recommendation 92/442/EEC of 27  July  1992 on the 
convergence of social  policy  objectives,  the  Council  recommends  that each Member State 
should  offer,  under  the  conditions  that  it  has  laid  down,  the  benefit  of its  human  health 
protection  system  to  persons  lawfully  residing  on  its  territory,  whatever the  level  of their 
income. 
Member States remain  responsible, of course, for the organisation and the financing of their 
social protection systems and are only conunitted in  respect of  the social protection objectives 
to be reached. 
C) Cost containment and the needs of the health policy 
Since  public  or social  insurance  funds  bear a  considerable  part of the  costs  related  to  the 
consumption of pharmaceutical  products,  health  authorities have  an  obvious and legitimate 
interest in  containing the  spending in  this area.  Moreover,  they  have an  interest in  ensuring 
that they get good value for the money spent. 
Most Member States have taken measures to contain spending on  medicinal  products. These 
vary  from  country  to  country and  include  direct  or indirect  controls  on  prices  or  profits, 
restrictions on the categories of products reimbursed, and percentage limits on the proportion 
of  spending reimbursed by the health and social security systems. 
On  the  other  hand,  Member  States  have  an  interest  in  maintaining  an  advanced  industry 
capable of continuous development and of supplying products which correspond to the needs 
of the health care sector.  It  is  therefore  important that the cost containment measures do  not 
hamper  industry's  capability  to  meet  these  demands.  Moreover,  national  cost  containment 
measures  should  not  provide  an  opportunity  for  arbitrary discrimination  or restrictions  of 
competition within the internal market. 
The divergence of national  pharmaceutical  pricing  and  reimbursement  systems  as  well  as 
cultural  differences  tend  to  make  the  European  market  for  pharmaceutical  products  more 
fragmented than is the case in the USA and Japan. Although price control and reimbursement 
systems  fall  within  the  competence of Member  States,  these  should  take  into  account the 
potential effects of such measures on  the functioning of  the internal market. The Commission 
will  see to  it  that any price control  system  is  operated  in  such a  way  that the  price setting 
mechanism is fully transparent and that all forms of  discrimination are prevented. 12 
Chapter3 
Growth, competitiveness, employment in the sector 
Several Community actions will soon ensure a quick access to the entire Community market, will 
create a more favourable environment for  R&D and  therapeutic innovation,  and will  facilitate 
access to third countries market for European companies.  The pharmaceutical  market  remains 
however fragmented, notably as a result of  social security and health policies. This has sometimes 
contributed to the lack of  transparency of  the EC pharmaceutical market. 
A) Cons_olidating the internal market in the pharmaceutical sector 
The main  measures  needed  for  the  completion of the  single  market  in  the  pharmaceutical 
sector have now been adopted. They will gradually come into effect over the coming months. 
1. Access to the market-European Medicines Evaluation Agency 
Since  1992, criteria and procedures for authorizing the marketing of human  and veterinary 
medicines, and for the inspection of  good manufacturing practices, are fully harmonized for all 
industrially produced medicinal products. 
In  June and July  1993  the EC  Council of Ministers adopted Regulation (EEC) 2309/93 and 
three Directives (93/39/EEC, 93/40/EEC and 93/41/EEC) laying down the future marketing 
authorization system for medicinal products for human and veterinary use and establishing the 
European Agency for the Evaluation of Medicinal Products. Thus, from  1995, firms wishing 
to gain rapid access to the single market will be able to choose between two procedures: 
• a  centralized procedure,  leading  to  a  single authorization for  the  whole  of the  European 
:  Community, reserved for certain new medicinal  products and mandatory for  those derived 
from biotechnology; 
• a  decentralized  procedure,  designed  for  most  medicinal  products, . based  on  mutual 
recognition  of national  marketing  authorizations  (with  disputes  to  be  settled  by  binding 
Community arbitration). 
The European Agency for the Evaluation of Medicinal Products,  which will  help  to operate 
the  system,  will  be  an  administrative  and  technical  secretariat  with  substantial  scientific 
support provided  by  the  competent  authorities of the  Member States.  Once  a  product  has 
undergone  one  of these  authorization  procedures,  the  Commission  will  tum the  Agency's 
opinion on it into a binding decision. 
The  future  marketing  authorization  system  should  give  firms  access  to  the  large  internal 
market  they  need  to  recoup  their  research  and  development  costs.  Sharing  the  workload 
between  the  European  Agency  and  existing national  ones  should  reduce  the  time  taken  to 
authorize a product from several years to 300 days, and halt runaway increases in  registration 
fees.  The greater transparency of the  European Agency's  evaluations and scientific opinions 
should help to restore consumer confidence, which is sometimes shaken by n:tarked differences 
ofviews between national authorities.  Public health will be better protected by pooling all the 13 
expertise available from various national authorities and by strengthening pharmacovigilancc. 
Tclematic  networks  should  in  particular  facilitate  notably  the  exchange  of information 
between national authorities. 
2. Transparency of  national price control measures 
Price control and reimbursement systems operated by some Member States contribute to the 
fragmentation  of the  EC  pharmaceutical  market.  It would  not  be  acceptable that  national 
decisions relating to· price fixing or admission for reimbursement are influenced by the origin 
of products and discriminate products imported from other Member States vis-a-vis domestic 
products. Some Member States have even used their price control or reimbursement system to· 
favour  inward  investment  (typically,  the  price  of medicinal  products  is  not  approved  or 
reimbursement is  not granted,  unless the  manufacturer  undertakes  to  invest  on  the national 
territory).  Such practices are,  of course,  contrary to  Article  30 of the  EC  Treaty,  and are 
challenged by the Commission each time they are brought to its attention. 
Council Directive 89/1 05/EEC relating to the transparency of measures regulating the pricing 
of medicinal  products  for  human  usc  and  their  inclusion  in  the  scope  of national  health 
insurance systems undoubtedly improved the transparency of national measures relating to the 
pricing  and  the  reimbursement  of  medicinal  products.  This  Directive  lays  down  the 
transparency  rules  that  Member  States  must  conform  to  in  this  field,  by  establishing  that 
national measures shall  be based on  objective and verifiable criteria and that all  individual 
decisions shall be duly motivated. However, despite the fact that all Member States have taken 
the  necessary  steps  to  formally  implement  this  Directive,  the  current  situation  remains 
unsatisfactory at times.  Further progress should  be  accomplished over the  next years  in  the 
framework  of an  improved  co-operation  between  Member States,  in  particular within  the 
Committee  instituted  by  the  Directive,  This  Committee constitutes  an  important forum  for 
discussion and exchange of  information in this field. 
3. Wholesale distribution, classification and advertising of  medicines 
The Community has no  intention to intervene directly in the fixing of intermediaries' margins, 
the  structure  of distribution  channels,  or  the  exercise  of the  pharmacists'  professional 
monopoly, so  long as these comply with  the  E.C.  Treaty.  However, two Council directives, 
which have just come into force, will help to approximate and rationalize distribution practices 
and some of  the rules governing the supply of medicinal products to the public. 
Firstly, Council  Directive 92/25/EEC on  the wholesale distribution of medicinal products for 
human use will facilitate and stimulate intra-Community trade whilst ensuring the integrity of 
the transactions involved ..  In  particular,  it  lays down  rules  for the recall  from  the market of 
defective products, and principles of  good distribution practice which should make it easier to 
detect counterfeit medicinal products. 
Secondly, Council Directive 92/26/EEC on classification for the supply of medicinal products 
for  human  use  harmonises  .classification  criteria  for  medicinal  products  which  may  be 
obtained  only  on  medical  prescription.  EC  citizens  travelling  within  the  Community  still 
encounter marked differences  in  rules governing their access to  medicinal  products, and the 
costly visit to a prescribing doctor required in one Member State may appear unjustified if no 
such visit is required in the next. 14 
After  intensive  consultations  with  European  organizations  representing  the  industry, 
consumers,  and  health  professionals,  the  Community  has  taken  a  series  of measures  to 
improve information for the proper usc of medicinal products, both to protect patients and to 
limit  the  cost of consumption  by  preventing  waste.  On  the  one  hand,  Council  Directive 
92/27/EEC, on the  labelling of medicinal  products  for  human  use and on  package  leaflets, 
aims to ensure that patient information  is  as  legible,  comprehensive and comprehensible as 
possible.  On the other hand,  Council  Directive 92/28/EEC on  the  advertising of medicinal 
products,  lays down  rules governing the advertising of these products to the general  public, 
including television and cross-frontier advertising, and requirements to be met by promotional 
activities directed at prescribing doctors and other health professionals. 
All the relevant EC rules, as laid down in  several regulations and directives, standard format 
for authorization applications, good clinical practice guidelines, guide to good manufacturing 
practice, etc, were brought together in an informal compilation entitled "The Rules Governing 
Medicinal  Products  for  Human  Use  in  the  European  Community"  (published  in  several 
volumes by the EC Official Publications Office). The Commission will soon start working on 
a  complete  recast  of the  EC  pharmaceutical  legislation  with  a  view  to.  making  it  more 
transparent and accessible to all interested parties. 
B) A better protection for therapeutic innovation and intellectual property 
The  research-based  pharmaceutical  industry  has  an  obvious  interest  in  the  quality  of 
protection afforded by industrial property rights to new medicinal products in the Community 
and in third countries. 
In theory, patents granted under the  Munich Convention, to which all EC  Member States are 
party, afford 20 years' protection, which runs  from the date the patent application is  filed.  In 
practice, by the time a medicinal  product has  been developed and a marketing authorisation 
obtained, only 8-10 years' protection remain. 
To  remedy  this  anomaly,  the  Council  adopted  Regulation  (EEC)  1768/92,  creating  a 
supplementary  protection  certificate  for  medicinal  products  to  provide  up  to  15  years' 
protection from the date of the first marketing authorisation in the Community. This gave the 
European industry better protection, similar to that obtained in the USA in  1984 and Japan in 
1986. 
The European industry has long been drawing the attention of the authorities to the need for 
providing better legal protection for biotechnological inventions.  · 
As  early  as. 1986,  the  Community  adopted  specific  provisions  (Directive  87/21/EEC) 
stipulating  that  a  minimum  period  must  elapse  between  the  grant  of the  first  marketing 
authorisation  for a new  medicinal  product (requiring comprehensive trials  to  prove quality, 
safety and efficacy) and the filing of  a second (abridged) application for the authorisation of a 
generic  copy  of this  product.  This  special  clause,  providing  I 0  years  protection  without 
prejudice to patent rights, was confirmed by the Council at the time of adoption of the future 
marketing authorisation for human and veterinary medicinal products. 
In  1992, the Commission has submitted to the Council a proposal for a directive on the legal 
protection of biotechnological inventions, the revised version of  which takes account of  certain 
ethical questions  raised  by  the  Parliament. The Council adopted a  common  position on  this IS 
text on 7 February 1994, which suggest that the text will  be definitely adopted by Parliament 
and Council sometime in  1994. 
However necessary, the protection of  therapeutic innovation alone will not suffice to establish 
an adequate environment for biotechnological R&D. 
C) A stable and safe environment for biotechnology 
In  its  White  Paper  - Growth,  Competitivity,  Employment  the  Commission  stressed  the 
importance of the biotechnological challenge for the Community. It identified the key factors 
that may jeopardise the expansion of applications in  those sectors based upon biotechnology. 
It  also  indicated  the  necessary  steps  needed  to  promote  the  competitiveness  of  the 
biotechnological  industry  on  the  one  hand,  and  to  ensure  the  correct  application  of 
biotechnology on the other hand. 
Among  unfavourable factors,  the  first  one to  note  is  the  shortfall  in  R&D  funding  in  the 
Community, which lags behind similar expenditures in  competing countries, and the fact that 
this shortfall  has not been  compensated by  privately financed  research  and development on 
biotechnology  in  the  Community.  It is  obvious  that  public  concerns  regarding  diffusion  of 
biotechnology are in general more pronounced in the Community than in the USA. 
Investment  in  biotechnology  should  increase,  focusing  on  the  most  vigorous  biotechnology 
R&D domains, and co-operation between the Community and Member States should improve 
in  order to avoid  duplication.  Moreover,  it  will  be  necessary  to  bring greater attention  to 
ethical questions associated with certain applications of biotechnology and to enhance public 
understanding about it.  In view of this, the Commission set up a Group of Advisers on Ethical 
Implications of  Biotechnology. 
In  general, the Community should  be  open  to  review  its  regulatory framework  applicable to 
biotechnology  in  the  light  of advances  in  scientific  knowledge,  in  order  to  ensure  that 
regulatory oversight is  based on  potential risks and to bring Community regulations closer in 
line  with  international  trends.  With  a  view  to  facilitating  the  diffusion  of these  new 
technologies whilst maintaining a high  level of protection of health and the environment, it is 
important  to  pool  the  existing  expertise  of the  Member  States  in  order  to  accelerate  the 
implementation of legislation,  to  make  it  more effective and  as  necessary,  to adapt it.  The 
Commission  regularly  reviews  the  legislation  relating to advances  in  biotechnology.  It is  in 
this  context that  it  is  currently  studying  the  means  of adapting  and  simplifying  Directives 
90/219!EEC  and  90/220/EEC  concerning  respectively,  the  contained  use  of genetically 
modified  micro-organisms,  and  the  deliberate  release  into  the  environment  of genetically 
modified organisms. 
This  applies  in  particular in  the  phannaceutical  sector,  which  is  one  of the  first  fields  of 
application  of  biotechnology.  The  localisation  of  fundamental  research,  of  laboratory 
experimentation and oftesting very often decides the localisation of  production. 
In  1986, the Council adopted, on the Commission's proposal, a  series of Directives for  high 
technology medicinal products, and in particular those derived from biotechnology. Since July 
1987, when Council Directive 87/22fEEC introduced a procedure for EC-wide "concertation" 
prior  to  any  national  decision  on  one  of these  products,  every  marketing  authorisation 
application  has  been  examined  jointly  by  all  the  Member  States.  The  Committee  for 
Proprietary  Medicinal  Products  has  evaluated  about  50  innovative  medicinal  products, 16 
including human  insulin,  synthetic growth  hormone,  erythropoietin, coagulation factor Vlll, 
hepatitis  B  vaccine,  interferons,  anti-AIDS  products,  etc.  The  Committee  for  Veterinary 
Medicinal Products has evaluated a dozen new biotechnology veterinary vaccines. 
To help  companies  to  determine  the  profiles  of their clinical  trials,  the  Commission,  after 
consulting  the  above  two  committees  and  their  working  parties  on  pharmaceutical 
biotechnology and veterinary immunology,  published a  series of manufacturing and  quality 
control guidelines for these new products.  Under the  future marketing authorisation system, 
these  medicinal  products  will  automatically  be  eligible  for  centralised  authorisation,  valid 
throughout  the  Community.  For  those  (rare)  medicinal  products  which  contain  genetically 
modified organisms, the Council has decided, as the Commission wished, to introduce a single 
evaluation  procedure,  to  be  performed  by  the  European  Agency  for  the  Evaluation  of 
Medicinal Products, in liaison with the bodies set up by the Community or the Member States. 
The pharmaceutical  industry has  many  years' experience of handling,  under stringent safety 
conditions, the pathological micro-organisms which arc used to manufacture vaccines for the 
diseases  that  they  cause.  New  biotechnological  techniques  may  offer  greater  safety,  and 
everyone  wants  the  first  effective  vaccines  for  AIDS  and  other  unbeaten  diseases  to  be 
developed as quickly as possible. Another promising line of research for  the coming years is 
genetic therapy to combat serious hereditary diseases, such as cystic fibrosis. 
D) Programmes better suited to pharmaceutical R&D 
One  of the  major  hindrances  to  the  efficiency  of research  is  its  fragmentation  among 
universities and institutes (which tend to organise their work along national lines). This makes 
it difficult for companies to exploit their results. This scattering and lack of co-ordination of 
scientific research  potential  is  prejudicial  to  scientific progress.  The remedy  is  to  encourage 
multi- and  inter-disciplinary  research  and  industry/university  interaction,  in  particular by 
exchanging researchers, as a means of  diffusing scientific knowledge. 
In  the  pharmaceutical  field,  it  is  often  difficult  to  dissociate  pre-normative  research  from 
research and development. The Community's draft proposal for a Council decision concerning 
the  fourth  framework  programme  of EC  activities  in  the  field  of research,  technological 
development  and  demonstration  (1994-1998)  seeks  to  tackle  this  specific  problem  by 
promoting integration and co-operation in R&D efforts. 
Furthermore,  to  allow  a  better  structured  pharmaceutical  research  within  the  Fourth 
framework programme (I  994-1998), a series of pilot projects was launched in  1992-93  (L~fe 
Science specific programme), the aim of which was to evolve research priorities in fields such 
as the development of in  vitro evaluation models,  the study of methodological  bases for the 
surveillance of adverse effects of medicinal products (pharmacovigilance), the exploration of 
new therapeutic approaches, and the setting up of  EC-wide networks for clinical trials. 
The success of these pilot projects, and the example of what is  happening in the USA,  have 
inspired  plans  for  more  intensive  Community action to  develop  the  scientific  and  technical 
bases needed to evaluate new medicinal products. 
The domain of research on "biomedicine and health" also aims to promote work on preventive 
medicines  (e.g.  vaccines) and rare diseases (orphan  drugs),  research into which may not be 
commercially  viable.  It will  take  into  account  the  needs  of the  functioning  of the  internal 
market  and  of the  setting  up  of the  European  Agency  for  the  Evaluation  of Medicinal 17 
Products. Besides direct scientific support, training schemes could be established to upgrade 
the  general  scientific and  technical  skills  of Agency  staff and  national  experts  evaluating 
medicinal products on the Agency's behalf. 
E) Towards a more competitive pharmaceutical market 
The pharmaceutical market is  not a  normal  market.  Companies channel  competitive efforts 
into  therapeutic  innovation  and  continued  improvements  to existing  products.  Competition 
between  companies  focuses  on  therapeutic  innovation.  Promotion  activities  with  health 
professionals play a key role.  Enterprises are therefore often less concerned about competing 
on prices, and rather concentrate on their costs, finances and sales volumes. 
Moreover,  some  Member  States  operate  a  price  control  system  for  reimbursed  medicinal 
products,  indeed even for  non-reimbursed medicines. The Commission is  prepared to address 
with the Member States the impact of  direct price control on competition and the management 
of health  expenditure.  In  the  case  of medicinal  products  which  arc  available  without 
prescription, and which arc not eligible for  reimbursement by social security, it seems that, in 
some Member  States,  the  market  is  often  competitive enough  to  ensure an  affordable  price 
level. 
In  the  case of reimbursed medicinal  products,  it  could be  interesting to  consider other cost 
containment measures.  Such methods would  be  based on competition  between  undertakings 
for those therapeutic categories where several treatments are available. 
From this  point of view,  the  launching of new truly  innovative  medicinal  products,  which 
bring about a significant therapeutic breakthrough, to the extent that they almost represent a 
new therapeutic category on their own, raises a serious problem which the Danish authorities 
have recently brought to  the attention of the  Council  and  the  Commission.  This concern  is 
obviously shared by  other  Member States.  The point  is  that Member States  should  not  be 
forced to accept excessive pricing of medicinal products which arc not subject to competition, 
whilst ensuring that the  pharmaceutical industry maintains its financial capacity necessary to 
support its R&D activities. The Commission is examining this problem in  close co-operation 
with the competent authorities of the Members States, notably within the Committee instituted 
by Directive 89/ I 05/EEC. 
It is, of course, for each Member State to appreciate, in  the light of the specificity of its own 
system,  which  measures  arc  most  likely  to  increase  competition  without jeopardising  the 
financial balance of social security budgets. This problem could be the subject of co-operation 
between Member States and, indeed, of  discussions at Community level. 
F) A more transparent pharmaceutical market 
If there is  little competition in the pham1aceutical market, it  is  probably because there is also 
little  transparency.  Social  security  institutions,  health  professionals  and  consumers  do  not 
benefit  from  sufficient  infonnation,  both  therapeutic  and  socio-economic,  on  the  various 
medicinal  products which  are available.  The pharmaceutical  industry  has  now grasped the 
need  to  open  a  dialogue  not  only  with  health  professionals  and  patients,  but  also  with 
politicians and the general public with a view to contributing to reforms in process. 
For its own part, the  Community already took several  initiatives towards more transparency 
on the pharmaceutical market. 18 
Firstly,  the  adoption  of the  new  Community  procedures  in  respect  of the  marketing 
authorisation of medicinal products, co-ordinated by the European Agency for the evaluation 
of  medicinal products, will in due course reduce the great diversity which can still be observed 
with  regard  to  various  characteristics  of medicinal  products:  different  information  about 
therapeutic indications, posology, side effects, presentation and package size specific to each 
market, differences in legal status, etc. 
Secondly,  several  Council  Directives  have  recently  been  implemented  by  Member  States. 
Directive  92/2 7/EEC  concerning  the  labelling  and  the  leaflet  of  medicinal  products 
substantially  reinforces the  relevant requirements  concerning  information conveyed to users 
and patients.  Directive 92/28/EEC strictly regulates advertising of medicinal  products to  the 
general  public,  promotion  with  health  professionals  (medical  representatives,  doctors' 
participation  in  conferences  and  meetings  organised  by  the  pharmaceutical  industry  for 
promotional  purpose,  distribution  of free  samples),  and  further  prohibits  all  incentives  to 
prescribe  or to  dispense  medicinal  products.  These  two  Directives  make  it  compulsory  to 
mention, in all communication about the medicinal  product, the common designation (generic 
name) of the product.  Directive 92/26/EEC lays down  common criteria for the classification 
of  medicinal products (products available on prescription only, and products available without 
prescription). 
Much has still to be  done, especially at national  level,  as regards the information for public 
authorities, health professionals and consumers about the cost of the various treatments which 
are available. The Commission, for its  part,  is endeavouring to develop in close co-operation 
with  Member  States  a  European  data  bank  on  medicinal  products  (ECPHIN  - European 
Community  Pharmaceutical  Products  Information  Network),  which  is  to  include,  besides 
information of a therapeutic nature, useful  socio-economic  information such as:  price of the 
medicinal  products, cost of the  treatment,  eligibility for  reimbursement, prescription only or 
non-prescription). The dissemination of  this information, which should ultimately be available 
for ·all health professionals and citizens throughout the Community, will  be greatly facilitated 
by the development oftelematic networks, notably by allowing interactive access to ECPHIN. 
In  this  context  it  is  worth  indicating  that  the  Commission  is  currently  considering  the 
modalities  of using  telematic  networks  for  the  exchange  of information  between  Member 
States,  the  Commission  and  the  future  European  Agency  for  the  evaluation  of medicinal 
products,  in  the  fields  of monitoring side-effects  to  mediCinal  products  (pharmacovigilance), 
scientific co-operation and evaluation of medicinal products. 
Lastly, the same medicinal  product is  often  sold  throughout the Community under different 
package sizes (number of units per pack). This complicates wholesale distribution and price 
comparisons,  and  is  likely  to  constitute  a  hindrance  for  the  free  movement  of products. 
Normalisation is probably the best way of  tackling this problem. 
G) Better use of medicinal products 
Greater  transparency  of the  phammceutical  market  should  benefit  social  security  bodies, 
health insurance funds, doctors, pharmacists, consumers. It could lead to a more rational use 
of  medicinal products and, ultimately, contribute to cost containment. Generally, awareness of 
the price of medicinal products whether by the health professional or the patient is  insufficient. 
The decision to  prescribe one  product or another  is  often  neglects  socio-economic  aspects. 19 
Efforts  to  improve  transparency  will  favour  multi-source  compet1t1on  (between  different 
uppliers of the same product containing the same active substance). Such efforts have been 
made by some Member States in  two ways:  promotion of parallel imports and of the  use of 
generic medicines.  Parallel  imports proliferate wherever prices  differ substantially  between 
national markets. The Court of Justice has on many occasions ruled that parallel imports are 
legal,  irrespective  of the  factors  that  determine  price  differences.  Various  actions  from 
pharmaceutical enterprises, such as resorting to different brand names for different markets, 
as well as State measures can substantially detract from  parallel imports.  Competition rules 
(Articles 85  and 86 EC) and provisions relating to the free movement of goods (Articles 30 
and 36 EC) allow the Commission to tackle these problems. 
Obviously, generic competition only arises when intellectual property protection conferred by 
the patent and, as the case may be, by the supplementary protection certificate, is  exhausted  .. 
Whenever  doctors  and  pharmacists  are  better  informed  about  the  cost  of the  various 
treatments which are available, they can select the treatment offering the  required therapeutic 
benefit which is less expensive for society. Thus, prescribing doctors, if better informed about 
the cost/efficacy ratio of medicinal  products will  tend  to  prescribe generically.  Pharmacists 
will tend to deliver the product offering the best value, if  the prescription allows it. 
Such measures should be supported by a significant effort in terms of health education of the 
population. Member States have developed numerous health campaigns, general or specific, in 
this field. If needed, these campaigns could be intensified or co-ordinated at Community level. 
H) A better access to third country markets 
In  all  industrialised countries,  the  pharmaceutical  industry  is  amongst the  most stringently 
regulated and controlled. This also explains that access to third country markets is  not easy. 
The Community, as the  world's  leading  producer and  exporter of medicinal  products,  has 
taken several international trade initiatives in order to favour exports. 
Within GATT, the Community has advocated the "zero-zero" option, i.e.  the total abolition of 
customs duties on pharmaceutical trade;  hence,  as a  net exporter of medicinal  products, the 
Community will  benefit from  the conclusion of the Uruguay Round, where this  option was 
upheld.  The part of the  Agreement  relating  to  TRIPS  (Trade-Related  Intellectual  Property 
Rights) was also supported by  the Conununity, which  regularly  leads  bilateral  initiatives to 
combat the counterfeiting of  medicinal products in certain third countries. 
The Community's success in harmonising pharmaceutical regulations has enabled it to take the 
initiative of progressively harmonising regulatory requirements with the  USA and Japan.  At 
the  first  International  Conference on  Ham10nisation  (ICH I)  held  in  Brussels  in  November 
1991, a  trilateral  programme of harmonisation,  spread over 5  years,  was adopted.  Further 
progress  was  made  at  the  second  conference  (ICH2)  in  Orlando,  in  November  1993. 
Eventually this work should eliminate unnecessary duplication of tests on human beings and 
on  animals,  which  should  also  help  to  reduce  global  research  costs.  A  third  conference 
(ICH3),  is  foreseen  in  Yokohama,  in  November  1995.  lt is  already  the  subject of intense 
scientific  consultations  between  the  Commission,  supported  by  experts  from  the  Member 
States  and  from  the  European  industry,  the  US  Food  and  Drug  Administration  and  the 
Japanese Ministry of  Health and Welfare. 20 
The Community  marketing authorisation,  aHer  evaluation  of the  medicinal  product  by  the 
European  Agency,  will  furthermore  supply  European  firms  with  a  prestigious  label  which 
should allow them  easier access to other important external  markets,  notably the  USA and 
Japan. 
The EC harmonisation process has had a significant impact on our EFT  A neighbours, through 
the agreement on the European Economic Area. Regular scientific consultations have enabled 
an easy adoption of  the pharmaceutical acquis communautaire. East and Central European 
countries  should  one  day  be  able  to  do  likewise,  and  have  already  begun  to  adopt  EC-
approved  good  manufacturing  practices.  The  Community  is  soon  to  join  the  European 
Pharmacopoeia Convention, which provides an ideal framework for co-operation with all these 
countries. 
The  Community  also  actively  promotes  bilateral  contacts  in  order  to  reduce  unjustified 
barriers to trade to pharmaceutical exchanges with its principal trade partners. 21 
Conclusion 
The European pharmaceutical industry needs a better integrated EC-wide market with more open 
competition to enable it to regain its competitiveness and remain a world player. 
The legitimate concern to limit public expenditure must not be allowed to jeopardise the future of 
pharmaceutical research in Europe. Public health and social security have nothing to gain from a 
weakening  of  the  European  pharmaceutical  industry,  because  a  substantial  share  of 
pharmaceutical spending will continue to have to be  reimbursed in any event, even  if innovative 
activity is pursued in the United States and Japan in the future. 
The  Commission,  for  its  part,  intends  to  intensify  the  dialogue  already  initiated  in  the 
pharmaceutical field with the Member States along the following lines: 
•  Consolidate and update the body of EC pharmaceutical legislation  in  a clear,  codified form 
which  makes  it  easy  for  companies  and  health  professionals  to  consult,  and  see  that 
Community legislation is fully and correctly transposed by the Member States; 
•  Introduce  the  future  marketing  authorisation  system  rapidly,  in  particular  by  helping  to 
establish the European Agency for the Evaluation of Medicinal Products, in close consultation 
with national authorities and interested firms. 
•  Enforce,  and  indeed  improve,  the  intellectual  property  protection  granted  to  genuine 
innovation  in  therapies,  in  order to  ensure  similar  protection  to  that available  in  the  main 
competitive markets. 
•  Create an environment more favourable to biotechnology by the adjustment of the regulatory 
framework to the needs of research and current international developments. 
•  Promote  the  integration  and  co-ordination  of  research  and  development  efforts  in  the 
pharmaceutical  industry  - this  is  moreover  one  of the  priority  objectives  of the  fourth 
framework programme for research and development in the Community ( 1994-1998). 
•  Monitor  the  impact  on  the  functioning  of the  internal  market  of national  pharmaceutical 
pricing  and  reimbursement  measures  in  order  to  avoid  any  discrimination  and  to  ensure 
transparency, and to assess the need to adapt Directive 8911 05/EEC in the light of  experience. 
•  Enhance  competition  in  the  pharmaceutical  market,  by  rendering  it  more  transparent  and 
allowing generic medicines to stimulate competition on price. 
•  Provide health professionals and consumers with the necessary information so as to promote 
the rational  use of medicinal  products,  notably  through  the  harmonisation of labelling and 
patient leaflets, and the setting up of  an computerised data bank on medicinal products, access 
to which should eventually be opened to the general public (ECPHIN). 
•  Pursue and intensify  harmonisation work,  across the Community and  world-wide  (ICH),  to 
reduce the cost of research  and development  in  the pharmaceutical sector and  facilitate  the 
access to external markets of  medicinal products manufactured in the Community. ·-
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Annex I 
The rules governing medicinal products 
in the European Community 
Volume I:  The rules governing medicinal  products  for human use in the 
European Community (Catalogue NO.·  C0-71-91-631-EN-C) 
Volume II:  Notice to applicants for marketing authorizations for medicinal 
products for human use in the Member States of  the European 
Community (Catalogue NO.·  CB-55-89-293-EN-C) 
Volume III:  Guidelines on the quality, safety and efficacy of  medicinal 
productsfor human use (Catalogue NO.·  CB-55-89-843-EN-C) 
Addendum N°  1, July /990 (Catalogue NO.·  CB-59-90-936-EN-C) 
Addemlum N°  2,  May 1992 (Catalogue NO.·  C0-75-92-558-EN-C) 
Volume IV:  Good  Manufacturing Practice for medicinal products 
(Catalogue NO.·  C0-71-91-760-EN-C) 
Volume V:  Veterinary Medicinal Products (Catalogue NO.·  C0-77-92-384-EN-C) 
N.B.  These texts, and the official journals cited, are on sale at the: 
Office for Official Publications of  the European Communities 
2 rue Mercier  L-2985 LUXEMBOURG 
Tel (352) 49 92 81  Fax (352) 49 00 03 MILLIONECU  1982 
APPARENf  27 311 
CON,SUMPTION 
PRODUCTION  30 122 
EXTRA-EC EXPORTS  4 334 
TRADE  BALANCE  2 811 
Member States 
Belgium 
Denmark 
Germany 
Greece 
Spain 
France 
Ireland 
Italy 
Luxembourg 
Netherlands 
Portugal 
United Kin_gdom 
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Annex It: 
·.  :'. 
:  . .',  ~  ·. 
Main ecOnomic indiCators 
.  (in current priceS). 
198J  1984  1985  1986  11187  1988 
'  30 018  33 250  34922  36 572  394%  45 492 
32997  36 619  38766  40 357  43 289  49460 
4 799  5 508  .6  193  6 246  6 302  6 817 
2979  3 428  3 843  .3 785  3 793  3 968 
Total expenditure on  Medicines ependiture 
health (as% of GNP)  (% health expenditures) 
6.3  16.8 
6.1  11.1 
13.1  15.9 
6.6  31.0 
5.3  14.3 
8.2  17.1 
6.6  07.7 
5.2  17.9 
9.9  07.7 
3.7  30.7 
6.7  11.6 
. 1989  ]<)90 
.50747  55065 
54 889  59103 
7621  7974 
4143  4038 
Medicines 
(%GDP) 
1.12 
0.66 
1.40 
1.90 
0.76 
1.40 
0.50 
0.93 
0.76 
0.67 
0.80 
1991  1991 
60 943  63 711 
65 324  68601 
9 124  10  559 
4 381  4 889 
Reimbursed 
medicines 
(%total) 
66 
61 
63 
70 
61 
64 
75 
69 
68 
62 
78 25 
Annex III 
Investment in  research and development 
as a percentage of production (per Member State) 
PRODUCTION  R&D SPENDING  R&D SPENDING 
MILLIONS ECU  MILLIONS ECU  % PRODUCTION 
EC  62185  6584  10.6 
Belgium  1718  206  11.2 
Denmark  1086  173  15.9 
Spain  5560  191  3.4 
France  13343  1578  ll.8 
Greece  456  - -
Ireland  792  - -
Italy  ll1ll  1008  9.1 
Netherlands  1568  221  14.1 
Portugal  686  - -
Germany  15085  1471  9.8 
UK  10780  1786  16.6 
Source : EFPIA 1991 5000 
M  4000 
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0 
n 
s  2000 
0 
f 
1000 
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u  0 
-1000 
Total 
world 
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Annex IV 
Trade balance of the Community 
for pharmaceuticals 
111111989 
1111990 
111991 
C1992 
EFTA  USA  Japan 
Source: Eu rostat 50 
45 
40 
35 
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%  25 
20 
15 
10 
5 
0 
1961-65 
27 
Annex V 
Geographical origin of new medicines 
(1961-1990) 
1966-70  1971-75  1976-80  1981-85  1986-90 
_._EC 
-B-USA 
_.,_Japan 
----*-Switz 
......._Others 
Source: Reis Arndt, Neue pharmazeutische Wirkstoffe 1961-1990) Phann. Ind. N 56, Nr I 1993 500000 
475000 
450000 
IIi 
§  425000 
1/) 
L.. 
~  400000 
'1-
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L..  375000 
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..0 
E 
~  350000 
300000 
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Annex VI 
Employment in the Community pharmaceutical industry 
(1981-1995) 
81  82  83  84  85  88  87  88  89  90  91  . 92  93  94  95  'lear 
p  9  9 
SOurce: "EFPIA en chiffres• 29 
Annex VII 
Price control, reimbursement and co-payment 
in the Member States 
Member State  Pricings  Reimbursement  Co-payment 
(1) 
Belgium  Price control  Positive list  25  - 50 - 60 - 80 % 
Denmark  Price freedom  Reference price  (2) 
Germany  Price freedom  Reference price  (2) 
-
Greece  Price control  Positive list  10 or 25% 
Spain  Price control 
Positive list 
10 or 40% 
+ negative list 
France  Price control  Positive list  35 or 65% 
Ireland 
Price freedom 
Positive list  (3)  + agreement with industry  --
Italy 
Price monitoring  Positive list  50 %or Lit 5000 
+reference to average EC price 
Luxembourg 
Price may not exceed price  Negative list  20% 
in the country of  origin 
Netherlands  Price freedom  Reference prices  (2) 
Portugal  Price control  Posi live list  30-60% 
--
UK 
Price freedom 
Selected list  £3.75 per item 
+ profit control 
Co-payment :  ( 1)  ln alll countries, dcrogutions arc provided tor social or therapeutic purpose. 
(2)  In reference price systems, the part of the price which exceeds the reference price is 
lanlamotmllo a co-payment.. 
(3)  No co-payment for the lower income group (approximately 37% of the population), other 
patients pay a maximum of£ 90 per calendar quarter for their prescribed mcdecines witl1 any 
excess expenditure over tl1al runow1t being refw1ded to tl1e patient by the health service. 
Source: Report on t11e measures taken by tl1e Member States for  t11e impalementation of Directive 891105/EEC 30 
Annex VIII 
Average prices in the Member States 
(EC = 100) 
Netherlands 
Ireland 
Denmark 
United Kingdom 
Belgium 
Germany 
Luxembourg 
Italy 
Spain 
Greece 
Portugal 
France  53 
Source: ABDA (Situation  1.1.93) 
85 
105 
97 
96 
94 
148 
133 
133 
123 
116 Belgium 
Germany 
Spain 
France 
Italy 
Netherlands 
United Kingdom 
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Annex IX 
Self-medication share 
of the pharmaceutical market 
Total market share(%) 
at public price level 
1988  1989  1990 
18  18  19 
16  16  17 
11  11  12 
19  20  20 
9  9  9 
9  10  10 
13  14  13 
Source: AESGPIIMS (1993) 
1991  1992 
18  17 
16  15 
11  11 
18  17 
8  8 
11  10 
13  12 32 
Annex  X 
Composition of price of medicinal product 
in the Member States 
(share of the manufacturer) 
c 
A- Manufacturing  40% 
B- R&D and licences  15% 
C-Medical information and advertising  15% 
D - Distribution  9 % 
E - Administration  II % 
F-Benefit and risk covering  10% 
Source : Phannalnfom1ation ISSN 0254-1475 
COM(93} 718 final 
DOCUMENTS 
EN  05  10 
Catalogue number: CB-C0-93-769-EN-C 
Office for Offidal Publications of the European Communities 
L-2985 Luxembourg 
ISBN 92-77-63816-8 